SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " opko " 10 found 🔀 AI-powered Shuffle
Is OPKO Health (OPK) Pricing In Too Much For Sales?
OPKO Health has seen sharp swings over the past few years, and the stock now sits at US$1.53 with investors reassessing what its current sales actually support. With such a mixed share price history and a changing business mix, the question is how much of the story around its revenue base is already priced in. Over the past 5 years the share price has fallen 58.5%, which puts the focus firmly on whether the current market value still lines up with what OPKO Health generates from its...
Labcorp to Acquire Select BioReference Health Assets for $722M
Labcorp to acquire select BioReference Health assets from OPKO Health for $722 million, including labs, service centers, and a prostate test.
Opko Health stock soars on $722M BioReference asset sale
Investing.com -- Opko Health Inc (NASDAQ:OPK) shares surged 20% in premarket trading Thursday after Labcorp Holdings Inc (NYSE:LH) agreed to acquire select assets of BioReference Health for $722 million in cash.
OPKO Health (OPK) Sharpens Its Focus, Is It Still A Bargain?
OPKO Health (OPK) has been drawing attention after recent trading moves around its US$1.56 share price, with investors weighing its mixed return profile over the past year against longer term performance trends. For context, OPKO Health’s recent pullback, with a 7 day share price return of down 4.29% and a 30 day share price return of down 4.88% from US$1.56, comes after a stronger 90 day share price return of 4.70% and year to date share price return of 22.83%. The 1 year total shareholder...
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
Conference Call to Begin Today at 4:30 p.m. ET MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a…...
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
Conference Call to Begin Today at 4:30 p.m. ET MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a…...
How Investors May Respond To OPKO Health (OPK) Boosting Its Nicoya Stake And RAYALDEE Milestones
In early June 2026, OPKO Health reported amending its agreement with Nicoya Therapeutics, gaining a 15% equity stake while maintaining eligibility for up to US$115.0 million in potential milestone payments tied to the commercialization of RAYALDEE for chronic kidney disease patients in Greater China and related territories. This deeper partnership not only expands OPKO’s economic interest in RAYALDEE but also tightens its alignment with Nicoya ahead of planned 2027 regulatory filings across...
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
Conference call begins at 4:30 p.m. Eastern time today MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports…...
OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results
Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports…...
OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 44th…...